Englander Institute for Precision Medicine

Publications

Found 12 results
Author Title Type [ Year(Asc)]
Filters: Author is Altorki, Nasser K  [Clear All Filters]
2024
Altorki NK, Walsh ZH, Melms JC, Port JL, Lee BE, Nasar A, Spinelli C, Caprio L, Rogava M, Ho P et al..  2024.  Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.. Nat Commun. 15(1):225.
Rowdo FPMadorsky, Xiao G, Khramtsova GF, Nguyen J, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK, Awuah B et al..  2024.  Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.. Cancer Lett. 584:216608.
Altorki NK, Bhinder B, Borczuk AC, Elemento O, Mittal V, McGraw TE.  2024.  A signature of enhanced proliferation associated with response and survival to anti-PD-L1 therapy in early-stage non-small cell lung cancer.. Cell Rep Med. :101438.
2023
Altorki NK, Walsh ZH, Melms JC, Port JL, Lee BE, Nasar A, Spinelli C, Caprio L, Rogava M, Ho P et al..  2023.  Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.. Nat Commun. 14(1):8435.
Rowdo FPMadorsky, Xiao G, Khramtsova GF, Nguyen J, Olopade OI, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK et al..  2023.  Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.. bioRxiv.
Dantas E, Murthy A, Ahmed T, Ahmed M, Ramsamooj S, Hurd MA, Lam T, Malbari M, Agrusa C, Elemento O et al..  2023.  TIMP1 is an early biomarker for detection and prognosis of lung cancer.. Clin Transl Med. 13(10):e1391.
Crowley MJP, Bhinder B, Markowitz GJ, Martin M, Verma A, Sandoval TA, Chae C-S, Yomtoubian S, Hu Y, Chopra S et al..  2023.  Tumor-intrinsic IRE1α signaling controls protective immunity in lung cancer.. Nat Commun. 14(1):120.
Rustam S, Hu Y, Mahjour SBabak, Rendeiro AF, Ravichandran H, Urso A, D'Ovidio F, Martinez FJ, Altorki NK, Richmond B et al..  2023.  A Unique Cellular Organization of Human Distal Airways and Its Disarray in Chronic Obstructive Pulmonary Disease.. Am J Respir Crit Care Med. 207(9):1171-1182.
2022
Altorki NK, Borczuk AC, Harrison S, Groner LK, Bhinder B, Mittal V, Elemento O, McGraw TE.  2022.  Global evolution of the tumor microenvironment associated with progression from preinvasive invasive to invasive human lung adenocarcinoma.. Cell Rep. 39(1):110639.
He Y, Kim I-K, Bian J, Polyzos A, Di Giammartino DCampigli, Zhang Y-W, Luo J, Hernandez MO, Kedei N, Cam M et al..  2022.  A Knock-In Mouse Model of Thymoma With the GTF2I L424H Mutation.. J Thorac Oncol. 17(12):1375-1386.
2021
Zoughbi WAl, Fox J, Beg S, Papp E, Hissong E, Ohara K, Keefer L, Sigouros M, Kane T, Bockelman D et al..  2021.  Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing.. Oncologist. 26(11):e1971-e1981.
2018
Markowitz GJ, Havel LS, Crowley MJp, Ban Y, Lee SB, Thalappillil JS, Narula N, Bhinder B, Elemento O, Wong STc et al..  2018.  Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.. JCI Insight. 3(13)